The landscape of the United States illicit drug market is shifting with terrifying speed. For several years, public health officials have struggled to contain the “fourth wave” of the opioid crisis, characterized by the adulteration of fentanyl with the veterinary sedative xylazine, commonly known as “tranq.” However, just as harm reduction strategies began to adapt to xylazine, a more potent and dangerous additive has emerged: medetomidine.
Often referred to on the streets as “Rhino Tranq” or “Tranq 2.0,” medetomidine is a powerful alpha-2 adrenergic agonist used in veterinary medicine for its anesthetic, sedative, and analgesic properties (NMS Labs, 2024). While it shares some chemical similarities with xylazine, its potency and physiological impact present a new tier of risk for people who use drugs.
Read the full article on the Catalyst Blog on CASAT OnDemand.
